Lilly Builds On Innovent Biologics Bet
This article was originally published in PharmAsia News
Lilly has expanded its cancer drug collaboration with Chinese biotech Innovent Biologics with plans to develop and market up to three anti-PD-1 based bi-specific antibodies over the next decade, both inside China's expanding healthcare market and abroad.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.